Ropeginterferon alfa-2b - PharmaEssentia

Drug Profile

Ropeginterferon alfa-2b - PharmaEssentia

Alternative Names: AOP-2014; P-1101; Peg-IFN-alpha-2b; PEG-P-IFN-alpha-2b; Pegylated proline interferon-alfa-2b

Latest Information Update: 07 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PharmaEssentia Corporation
  • Developer AOP Orphan Pharmaceuticals AG; Institute of Liver and Biliary Sciences; Mayo Clinic; National Cancer Institute (USA); PharmaEssentia Corporation
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols; Small molecules
  • Mechanism of Action Interferon alpha 2b stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Polycythaemia vera
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Polycythaemia vera
  • Phase III Essential thrombocythaemia; Hepatitis B
  • Phase II Chronic myeloid leukaemia; Hepatitis C; Myelofibrosis
  • Preclinical Cancer

Most Recent Events

  • 25 Jan 2018 AOP Orphan Pharmaceuticals completes the phase I/II PEGINVERA trial for Polycythaemia vera in Austria (NCT01193699)
  • 10 Dec 2017 Long term follow up data from the phase III CONTI-PV trial in Polycythemica vera presented at the American Society of Hematology Annual Meeting 2017 (ASH-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Hepatitis-B(In volunteers) in Canada (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top